What is ART-TG ?

The Technological Research Accelerator in Genomic Therapy (ART-TG) was established by Inserm, the french national biomedical institution, to promote excellence in gene therapy research. ART-TG is a center for technological innovation and to advance novel cell and gene therapy concepts towards industrial or clinical phases.  

What does ART-TG do ?

ART-TG is a pre-GMP stage R&D laboratory with pharmaceutical expertise. It is expert in ex vivo gene therapy and genome editing technologies. ART-TG develops new therapies, new devices and new processes to produce vectors or gene-modified cells.

 

What are the domains of interest for ART-TG ?

Two fields in which gene therapy has high innovation potential:

     immunotherapy of cancer or of infectious diseases,

     treatment of genetic disorders of the blood or of the immune system.

Where is ART-TG located ?

ART-TG is located within the Genopole campus, south of Paris, France.​

What is MAGENTA ?

MAGENTA is one of the first industrial integrators that were established in 2020 by the french government to address the challenges of industrial production of biomedicines. MAGENTA was co-founded by ART-TG and by Cithera to foster innovation in cell and gene therapy at the public/private interface.

 

Contact us:
ART-TG seeks partners looking to innovate in the field of genomic therapy.
Inserm Transfert accompanies the partnerships of ART-TG.  

art-tg@inserm.fr

logo_inserm.jpg
logo_genopole.png
logo_magenta.png
logo_insermtransfert.png

Team

IMGP1207.JPG

Anne Galy, PharmD, PhD
Director 
(ORCID)
CV online

 

mario_amendola.png

Mario Amendola, PhD

Expert Genome Editing
(ORCID)

Our projects are funded by

logo_inserm_edited.jpg
Inserm_logo_anrs.jpg
Agence_Nationale_de_la_Recherche_edited.
imi_logo.png
téléchargement.png
vri.jpg
logo_ridf.jpg
logo_dim_tg.jpg
logo_dim1_health.png
logo_genopole.png
inca-345x190_7.jpg
logobpi.png